Jubilant Pharma has posted its Q1FY22 results. In the quarter, the consolidated revenue was Rs 1,635 crore versus Rs 1,156 crore in Q1'FY21. The total EBITDA was at Rs 379 crore versus Rs 183 Crore in Q1’FY21. Finance costs have been reported at Rs 35 crore versus Rs 48 crore in Q1'FY21. The average blended interest rate for Q1'FY22 stood at 4.64 per cent versus 5.26 per cent in Q1’FY21. Profit after tax was at Rs 160 crore as compared to Rs 35 crore in Q1'FY21. EPS was at Rs 10.1 versus Rs 2.2 in Q1'FY21. The capital expenditure for the quarter was at Rs 106 crore.

Commenting on company’s performance, Shyam S Bhartia, Chairman and Hari S Bhartia, Co-Chairman and MD, Jubilant Pharmova said, "During this quarter, in addition to YoY increase, we also reported sequential improvement in the speciality pharma segment with gradual recovery across radiopharmaceuticals, radiopharmacy and allergy business. In radiopharmaceuticals, we have enhanced efforts to promote existing products as well as expand our product pipeline with strategic partnerships. With a gradual recovery in nuclear medicine procedures, the turnaround plan of the radiopharmacy business is on track. CMO business continued to benefit from COVID related deals. Contract Research and Development Services business witnessed strong YoY growth in revenues led by healthy demand from customers. We have doubled our chemistry research capacity and the facility is operational now. Despite COVID-19 related lockdowns, we have been able to ensure continuity in most of our manufacturing operations across all business segments while at the same time ensuring the safety of our employees."